WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 407125
Description: SCH-51344 is an inhibitor of RAS/RAC-mediated cell morphology pathway. RAS interacts with multiple targets in the cell and controls at least two signaling pathways, one regulating extracellular signal-regulated kinase (ERK) activation and the other controlling membrane ruffling formation. SCH 51344 specifically blocks membrane ruffling induced by activated forms of H-RAS, K-RAS, N-RAS, and RAC. SCH 51344 was effective in inhibiting the anchorage-independent growth of Rat-2 fibroblast cells transformed by the three forms of oncogenic RAS and RAC V12.
MedKoo Cat#: 407125
Chemical Formula: C16H20N4O3
Exact Mass: 316.15354
Molecular Weight: 316.36
Elemental Analysis: C, 60.75; H, 6.37; N, 17.71; O, 15.17
Synonym: SCH-51344; SCH 51344; SCH51344.
IUPAC/Chemical Name: 2-(2-((6-methoxy-3-methyl-1H-pyrazolo[3,4-b]quinolin-4-yl)amino)ethoxy)ethan-1-ol
SMILES Code: CC1=NNC2=NC3=CC=C(OC)C=C3C(NCCOCCO)=C21
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
The following data is based on the product molecular weight 316.36 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Huber KV, Salah E, Radic B, Gridling M, Elkins JM, Stukalov A, Jemth AS, Göktürk C, Sanjiv K, Strömberg K, Pham T, Berglund UW, Colinge J, Bennett KL, Loizou JI, Helleday T, Knapp S, Superti-Furga G. Stereospecific targeting of MTH1 by (S)-crizotinib as an anticancer strategy. Nature. 2014 Apr 10;508(7495):222-7. doi: 10.1038/nature13194. Epub 2014 Apr 2. PubMed PMID: 24695225; PubMed Central PMCID: PMC4150021.
2: Gelman IH, Xi Q, Kumar CC. Reexpression of the major PKC substrate, SSeCKS, correlates with the tumor-suppressive effects of SCH51344 on rat-6/src and rat-6/ras fibroblasts but not on rat-6/raf fibroblasts. Ann N Y Acad Sci. 1999;886:221-4. PubMed PMID: 10667224.
3: Kumar CC, Ohashi K, Nagata K, Walsh A, Bar-Sagi D, Mizuno K. SCH 51344, an inhibitor of RAS/RAC-mediated cell morphology pathway. Ann N Y Acad Sci. 1999;886:122-31. Review. PubMed PMID: 10667210.
4: He H, Watanabe T, Zhan X, Huang C, Schuuring E, Fukami K, Takenawa T, Kumar CC, Simpson RJ, Maruta H. Role of phosphatidylinositol 4,5-bisphosphate in Ras/Rac-induced disruption of the cortactin-actomyosin II complex and malignant transformation. Mol Cell Biol. 1998 Jul;18(7):3829-37. PubMed PMID: 9632767; PubMed Central PMCID: PMC108967.
5: Walsh AB, Dhanasekaran M, Bar-Sagi D, Kumar CC. SCH 51344-induced reversal of RAS-transformation is accompanied by the specific inhibition of the RAS and RAC-dependent cell morphology pathway. Oncogene. 1997 Nov 20;15(21):2553-60. PubMed PMID: 9399643.
6: Kumar CC. [Inhibition of RAS-transformation by SCH51344]. Gan To Kagaku Ryoho. 1997 Sep;24(11):1503-11. Review. Japanese. PubMed PMID: 9309148.
7: Kumar CC, Prorock-Rogers C, Kelly J, Dong Z, Lin JJ, Armstrong L, Kung HF, Weber MJ, Afonso A. SCH 51344 inhibits ras transformation by a novel mechanism. Cancer Res. 1995 Nov 1;55(21):5106-17. PubMed PMID: 7585559.